Alamandin and especially melatonin attenuate pulmonary arterial hypertension induced by monocrotalin
ALA, MEL, and ALA + MEL attenuate PAH and protect RV via antiproliferative, anti-remodeling, antihypertrophic, anti-inflammatory, and free radical scavenging (only MEL) capabilities. Overall, MEL produced the best outcomes.
Authors
- Ertuğrul Kılıç (ORCID: https://orcid.org/0000-0001-6494-8923)
- Samir Abbas Ali Noma
- Mehmet Günata (ORCID: https://orcid.org/0000-0001-6905-4259)
- Azibe Yıldız (ORCID: https://orcid.org/0000-0001-5686-7867)
- Seyhan Ayik (ORCID: https://orcid.org/0000-0002-8766-9094)
- Ahmet Ulu (ORCID: https://orcid.org/0000-0002-4447-6233)
- Hakan Parlakpınar (ORCID: https://orcid.org/0000-0001-9497-3468)
- Onural Özhan (ORCID: https://orcid.org/0000-0001-9018-7849)
- S. Inan (ORCID: https://orcid.org/0000-0001-8274-7914)
- Necip Ermiş (ORCID: https://orcid.org/0000-0001-6781-7478)
- Nigar Vardı (ORCID: https://orcid.org/0000-0003-0576-1696)
- Ahmet Acet (ORCID: https://orcid.org/0000-0003-1131-1878)
- Emre Sonmez (ORCID: https://orcid.org/0009-0006-9944-6994)
- Nilay Ates
Institutions
- Inonu University (TR)
- Istanbul Medipol University (TR)
Publication Details
- Journal
- Fundamental and Clinical Pharmacology
- Published
- 2024-08-11
- DOI
- https://doi.org/10.1111/fcp.13033
- Citations
- 4
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- Inönü Üniversitesi